Beyond The Numbers: 8 Analysts Discuss Ocular Therapeutix Stock
Portfolio Pulse from Benzinga Insights
Analysts' ratings for Ocular Therapeutix (NASDAQ:OCUL) vary from bullish to bearish, with 8 analysts providing insights. The average 12-month price target is $14.0, a slight decrease from the previous $14.50. Key analysts have maintained, raised, or lowered their ratings and price targets based on recent developments. Ocular Therapeutix has shown notable revenue growth but faces challenges in profitability and returns.
August 01, 2024 | 6:05 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Ocular Therapeutix (NASDAQ:OCUL) has received mixed ratings from analysts, with an average 12-month price target of $14.0, down from $14.50. The company has shown revenue growth but struggles with profitability and returns.
The mixed analyst ratings and slight decrease in the average price target suggest a neutral short-term impact on OCUL's stock price. While revenue growth is positive, challenges in profitability and returns may offset this, leading to a balanced outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100